161 related articles for article (PubMed ID: 37768505)
1. Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study.
Wu CY; Wang Q; Shi J; Zhang XY; Du R; Gu JR; Liu QH; Yu J; Xu JW; Zhang YJ; Zhu H; Li MT; Zeng XF
Rheumatol Ther; 2023 Dec; 10(6):1609-1622. PubMed ID: 37768505
[TBL] [Abstract][Full Text] [Related]
2. Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials.
Chen YC; Yoo DH; Lee CK; Li KJ; Won JE; Wu WS; Zhong J; Nicolay C; Walls CD; Tanaka Y
Int J Rheum Dis; 2020 Jan; 23(1):65-73. PubMed ID: 31729189
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
[No Abstract] [Full Text] [Related]
4. Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases.
Salinas CA; Louder A; Polinski J; Zhang TC; Bower H; Phillips S; Song Y; Rashidi E; Bosan R; Chang HC; Foster N; Gershenson B; Yamanaka H; Kishimoto M; Tanaka Y; Fischer P; Zhu B; Faries D; Mai X; Doherty BT; Grelaud A; Thurin NH; Askling J; Deberdt W;
Rheumatol Ther; 2023 Feb; 10(1):201-223. PubMed ID: 36371760
[TBL] [Abstract][Full Text] [Related]
5. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of baricitinib in rheumatoid arthritis: a monocentric, longitudinal, real-life experience.
Spinelli FR; Ceccarelli F; Garufi C; Duca I; Mancuso S; Cipriano E; Dell'Unto E; Alessandri C; Di Franco M; Perricone C; Priori R; Riccieri V; Scrivo R; Sili Scavalli A; Truglia S; Valesini G; Conti F
Clin Exp Rheumatol; 2021; 39(3):525-531. PubMed ID: 33337992
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance.
Takagi M; Atsumi T; Matsuno H; Tamura N; Fujii T; Okamoto N; Takahashi N; Nakajima A; Nakajima A; Tsujimoto N; Nishikawa A; Ishii T; Takeuchi T; Kuwana M
Mod Rheumatol; 2023 Jul; 33(4):647-656. PubMed ID: 35932218
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study).
Hernández-Cruz B; Rosas J; Díaz-Torné C; Belzunegui J; García-Vicuña R; Inciarte-Mundo J; Pons A; Millán AM; Jeria-Navarro S; Valero JA; García-Castañeda N; Valero C; Llorente I; Calvo A; Díaz-Cerezo S; Núñez M
Rheumatol Ther; 2022 Apr; 9(2):589-608. PubMed ID: 35041155
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
Li Z; Hu J; Bao C; Li X; Li X; Xu J; Spindler AJ; Zhang X; Xu J; He D; Li Z; Wang G; Yang Y; Wu H; Ji F; Tao H; Zhan L; Bai F; Rooney TP; Zerbini CAF
Clin Exp Rheumatol; 2020; 38(4):732-741. PubMed ID: 32452344
[TBL] [Abstract][Full Text] [Related]
10. Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Taylor PC; Bieber T; Alten R; Witte T; Galloway J; Deberdt W; Issa M; Haladyj E; De La Torre I; Grond S; Wollenberg A
Adv Ther; 2023 Apr; 40(4):1867-1883. PubMed ID: 36802049
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.
Yang Y; Li XF; Zhang X; Bao CD; Hu JK; Xu JH; Li XP; Xu J; He DY; Li ZJ; Wang GC; Wu HJ; Ji F; Zhan LJ; Zerbini CAF; Li ZG
Rheumatol Ther; 2020 Dec; 7(4):851-866. PubMed ID: 32876903
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a
Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.
Genovese MC; Smolen JS; Takeuchi T; Burmester G; Brinker D; Rooney TP; Zhong J; Daojun M; Saifan C; Cardoso A; Issa M; Wu WS; Winthrop KL
Lancet Rheumatol; 2020 Jun; 2(6):e347-e357. PubMed ID: 38273598
[TBL] [Abstract][Full Text] [Related]
14. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.
Kuwana M; Sugiyama N; Momohara S; Atsumi T; Takei S; Tamura N; Harigai M; Fujii T; Matsuno H; Takeuchi T; Yamamoto K; Takasaki Y; Tanigawa M; Endo Y; Hirose T; Morishima Y; Yoshii N; Mimori T; Takagi M
Mod Rheumatol; 2024 Feb; 34(2):272-286. PubMed ID: 37405710
[TBL] [Abstract][Full Text] [Related]
15. Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis.
Hernández-Cruz B; Kiltz U; Avouac J; Treuer T; Haladyj E; Gerwien J; Gupta CD; Conti F
Rheumatol Ther; 2023 Dec; 10(6):1417-1457. PubMed ID: 37715917
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
[TBL] [Abstract][Full Text] [Related]
17. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG
Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533
[TBL] [Abstract][Full Text] [Related]
18. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
19. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
Cai W; Tong R; Sun Y; Yao Y; Zhang J
Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
